Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells
- PMID: 17191900
- DOI: 10.1002/cbdv.200490081
Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells
Abstract
Thymosin beta4 (Tbeta4), a 5 kDa polypeptide, is a member of the beta-thymosin family. It acts as the principal intracellular G-actin sequestering peptide and exhibits extracellular functions in angiogenesis and wound healing. The N-terminus of Tbeta4 contains a bioactive tetrapeptide, acSDKP, a negative regulator of hematopoietic stem-cell proliferation. Here, we show that both peptides inhibit mast-cell proliferation over the concentration range of 10(-6) to 10(-17) M with the maximum effect of both at 10(-14) M. Both Tbeta4 and acSDKP caused dysplastic mast-cell nuclei that were confirmed by DAPI fluorescent staining. Flow-cytometric analysis of ploidy revealed that the dysplastic nuclei were not multinucleated, but fragmented nuclei in G2 growth arrest. We could further demonstrate that 10(-8) or 10(-14) M Tbeta4 or acSDKP induce mast-cell degranulation. A concentration of 10(-8) M Tbeta4 or acSDKP caused 57 or 89% degranulation, respectively. A number of tryptic fragments of Tbeta4 were assayed beside intact Tbeta4 and the tetrapeptide, and found to be inactive.
Similar articles
-
Thymosin beta4 and AcSDKP inhibit the proliferation of HL-60 cells and induce their differentiation and apoptosis.Cell Biol Int. 2006 Jun;30(6):514-20. doi: 10.1016/j.cellbi.2006.01.009. Epub 2006 Mar 6. Cell Biol Int. 2006. PMID: 16677835
-
Thymosin beta4 and thymosin beta4-derived peptides induce mast cell exocytosis.Peptides. 2007 Apr;28(4):752-9. doi: 10.1016/j.peptides.2007.01.004. Epub 2007 Jan 13. Peptides. 2007. PMID: 17289217
-
Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP.Exp Hematol. 2001 Jan;29(1):12-8. doi: 10.1016/s0301-472x(00)00634-2. Exp Hematol. 2001. PMID: 11164101
-
Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases.Ann N Y Acad Sci. 2010 Apr;1194:53-9. doi: 10.1111/j.1749-6632.2010.05488.x. Ann N Y Acad Sci. 2010. PMID: 20536450 Review.
-
Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells.Vitam Horm. 2016;102:121-49. doi: 10.1016/bs.vh.2016.04.011. Epub 2016 May 31. Vitam Horm. 2016. PMID: 27450733 Review.
Cited by
-
Exogenous thymosin beta4 prevents apoptosis in human intervertebral annulus cells in vitro.Biotech Histochem. 2009 Dec;84(6):287-94. doi: 10.3109/10520290903116884. Biotech Histochem. 2009. PMID: 20055734 Free PMC article.
-
Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK.FASEB J. 2011 Jun;25(6):1815-26. doi: 10.1096/fj.10-167940. Epub 2011 Feb 22. FASEB J. 2011. PMID: 21343177 Free PMC article.
-
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Haematologica. 2010 Jan;95(1):163-7. doi: 10.3324/haematol.2009.006411. Epub 2009 Oct 14. Haematologica. 2010. PMID: 19833631 Free PMC article.
-
Thymosin beta4 and Ac-SDKP: tools to mend a broken heart.J Mol Med (Berl). 2008 Jan;86(1):29-35. doi: 10.1007/s00109-007-0243-9. Epub 2007 Aug 15. J Mol Med (Berl). 2008. PMID: 17701149 Review.
-
Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.Clin Ophthalmol. 2007 Sep;1(3):201-7. Clin Ophthalmol. 2007. PMID: 19668473 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources